Memphasys Ltd (MEM) AI Stock Analysis

• Market Cap: AU$9.92M
• Dividend Yield: N/A
• Average Volume (3M): 5.82M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.49
• Revenue Growth: -41.19%
• EPS Growth: 20.93%
• Country: AU
• Employees: 24
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 1,983,598,100
• 10 Day Avg. Volume: 10,733,247
• 30 Day Avg. Volume: 5,820,782
• PEG Ratio: -0.35
• Price to Book (P/B): 1.03
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.54
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: ―

Memphasys Ltd faces significant financial challenges, including high debt levels and negative profitability, leading to a low financial performance score. The lack of technical data adds uncertainty to market perceptions. Valuation metrics suggest potential if fundamental improvements occur. Overall, the stock is precarious, with substantial risks that need addressing for long-term viability.

Memphasys Ltd Business Overview & Revenue Model

Company Description

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a novel automated device for quickly and gently separating high quality sperm from a raw semen sample for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a central lab human semen analysis from distantly located donors; and AI-Port. An ambient temperature semen transport device used for animal artificial insemination. Memphasys Limited was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. The company was incorporated in 2006 and is based in Homebush, Australia.

How the Company Makes Money

Memphasys Ltd generates revenue through the sale of its proprietary fertility treatment technologies, such as the Felix device. The company earns money by selling these devices to fertility clinics and other healthcare providers involved in assisted reproductive technologies. Additionally, Memphasys may engage in strategic partnerships and collaborations with other biotech firms, research institutions, or healthcare providers to further develop and market its technologies, potentially generating additional revenue streams. As the company continues to innovate and expand its product offerings, it seeks to increase market penetration and drive sales growth in the reproductive health sector.

Memphasys Ltd Financial Statement Overview

Summary

Memphasys Ltd operates in the biotechnology sector, facing consistent profitability and cash flow challenges despite recent revenue growth. The high debt levels and continuous net losses present significant risks, though external financing has temporarily stabilized operations. Improvement in cost management and profitability is essential for long-term sustainability.

Income Statement

Memphasys Ltd has shown some revenue growth, increasing from $15,371 in 2023 to $60,000 in 2024, representing a strong growth rate. However, the company consistently reports negative gross profit, indicating high cost of goods sold relative to revenue. Net profit margins remain negative, driven by substantial net losses, suggesting ongoing profitability challenges.

Balance Sheet

The company maintains a high debt-to-equity ratio indicative of significant leverage, which could pose financial risks. Stockholders' equity has decreased slightly over time. The equity ratio is stable but not high, indicating moderate reliance on equity financing. Overall, the balance sheet reflects a leveraged financial structure with potential risk but some stability in equity.

Cash Flow

Memphasys Ltd's cash flow statement shows negative free cash flow, reflecting operating challenges. Operating cash flow to net income ratio is negative, indicating insufficient cash generation to cover losses. Financing cash flows are positive, highlighting reliance on external financing to support operations.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	60.00K	15.37K	27.15K	211.48K	0.00
Gross Profit	-1.57M	-824.86K	-922.60K	-48.00K	-196.23K
EBITDA	-3.31M	-2.36M	-1.39M	-1.14M	-869.05K
Net Income	-4.44M	-3.40M	-2.08M	-1.49M	-1.13M
Balance Sheet
Total Assets	12.43M	14.67M	14.12M	14.58M	11.30M
Cash, Cash Equivalents and Short-Term Investments	277.80K	680.58K	311.83K	2.05M	2.01M
Total Debt	4.81M	6.37M	5.56M	5.36M	1.04M
Total Liabilities	5.59M	7.28M	6.47M	5.97M	1.54M
Stockholders Equity	6.84M	7.38M	7.65M	8.61M	9.76M
Cash Flow
Free Cash Flow	-3.87M	-3.23M	-2.61M	-2.96M	-3.02M
Operating Cash Flow	-3.23M	-1.41M	311.82K	47.25K	120.19K
Investing Cash Flow	-711.05K	-1.98M	-3.08M	-3.00M	-3.14M
Financing Cash Flow	3.54M	3.75M	1.03M	2.99M	4.11M

Memphasys Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	HK$17.39B	5.61	-7.44%	3.56%	11.55%	-28.15%
MEM	37 Underperform	AU$9.92M	―	-80.47%	―	-41.19%	20.93%
LVCLF	―	$6.60M	―	-43.32%	―	―	―
CMB	―	AU$5.85M	―	-983.90%	―	―	―
1AD	46 Neutral	AU$2.23M	―	-392.18%	―	―	34.26%
AVE	46 Neutral	$14.28M	―	-64.72%	―	139.19%	33.33%
CHM	42 Neutral	AU$9.75M	―	-180.09%	―	―	28.57%

Memphasys Ltd Corporate Events

Memphasys Limited Announces Board Changes with Departure of Non-Executive Director

Memphasys Limited announced the resignation of Mr. Michael Atkins as Non-Executive Director due to competing time commitments. Mr. Atkins, who joined the board in March 2024, contributed significantly with his expertise in capital markets and corporate governance. The company expressed gratitude for his strategic insights during his tenure. To ensure continued growth and expertise in commercialisation and global market development, the board recently appointed Mr. Marjan Mikel, whose skill set complements the company’s strategic objectives in the reproductive health sector.

Memphasys Limited Announces Venue Change for General Meeting

Memphasys Limited has announced a change in the venue for its upcoming General Meeting, scheduled for 8 August 2025. The meeting will now be held at Level 32/200 George Street, and shareholders can participate by lodging proxy forms or attending in person. This change does not affect any other details previously released about the meeting.

Memphasys Ltd Announces Key Shareholder Meeting

Memphasys Ltd has announced a General Meeting scheduled for August 8, 2025, where shareholders will vote on several key resolutions. These include the ratification of prior share and option issues under the May 2025 placement and the appointment of BDO Audit Pty Ltd as the company’s external auditors. This meeting is significant as it involves decisions that could impact the company’s financial structuring and governance, potentially influencing shareholder value and the company’s strategic direction.

Memphasys Advances Global Strategy with CE Mark Application for Felix™

Memphasys Limited has submitted a CE Mark application for its Felix™ sperm separation device, marking a significant step in its global commercialization strategy. This milestone is expected to unlock commercial access in the EU and accelerate approvals in other regions, enhancing the company’s market positioning in the rapidly growing IVF sector. The Felix™ device offers a significant reduction in sperm preparation time, which is crucial for improving efficiency in fertility clinics. Memphasys is adopting a direct commercialization approach in markets with lower regulatory requirements, such as Japan, Canada, and New Zealand, to build early momentum and demonstrate the device’s value, while strategic distribution partnerships remain a long-term focus.

Memphasys Appoints Marjan Mikel as Non-Executive Director to Boost Global Expansion

Memphasys Limited has appointed Marjan Mikel as a Non-Executive Director, bringing extensive experience in business development and commercialisation across the Medtech, diagnostics, healthcare services, and life sciences sectors. Mikel’s previous roles and familiarity with Memphasys’ strategic vision are expected to aid the company’s global expansion of its Felix™ system and accelerate the commercialisation of the RoXsta™ platform.

Memphasys Limited Appoints New Auditor Amidst Strategic Commercialization Efforts

Memphasys Limited has announced a change in its external auditors, appointing BDO Audit Pty Ltd following the resignation of Pitcher Partners. This decision comes as part of a corporate review by the Board, aligning with the company’s strategic move towards the international commercialization of its Felix™ Device.